Positive meeting with Medical Products Agency prior to clinical Phase II trial

Redwood Pharma has met with the Swedish Medical Products Agency in an advisory discussion. The meeting gave the company the opportunity to present its development and clinical plans for RP101, which will be tested in a clinical Phase II study in women suffering from chronic dry eye disease.

The meeting gave Redwood Pharma the opportunity to address important questions in an effort to confirm, optimize, and where necessary, modify the company’s plans. Furthermore, the meeting generated valuable advice in advance of the future clinical Phase III trial that Redwood Pharma intends to carry out in partnership with a larger pharmaceutical firm.

“We have come a long way in the development of our pharmaceutical drug candidate RP101, and with this meeting, intended to gain the Agency’s view of our development plan. As a result of the meeting, we feel ever more committed to follow through with our RP101 project as planned,” says CEO Martin Vidaeus.

About RP101

RP101 is the company’s lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal women. The active substance is an endogenous small molecule already proven safe and effective and has been formulated in IntelliGel to control its release, reduce dosing and increase compliance. Redwood Pharma will initiate a clinical Phase II trial of RP101 in Europe. Dry eye disease is a large market with serious unmet needs – estimated to grow to USD 2.7 billion in 2022. RP101 will be the first therapy targeted towards a unique biological mechanism and the target patient population of postmenopausal women. With prior development data, this program will be faster to market and has lower capital needs and development risks than programs based on New Chemical Entities.

This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, February 26, 2018.

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit: www.redwoodpharma.com